Last updated: April 23, 2026
What is Telavancin Hydrochloride in the supply chain context?
Telavancin hydrochloride is an antibacterial active pharmaceutical ingredient (API) used in the brand TELAVANCIN (often referenced as telavancin) drug product supply ecosystem. In practice, the “supplier” question splits into two procurement lanes: API (active) manufacturers and drug product / formulation supply. For telavancin hydrochloride specifically, supplier lists depend on whether the buyer seeks manufacturing of API or finished dosage form.
Who are the known suppliers/manufacturers for telavancin hydrochloride?
Based on public regulatory and labeling disclosures that typically name manufacturers for the drug substance and/or drug product, telavancin supply commonly traces to a limited set of original and follow-on manufacturing entities.
API and drug substance manufacturing (named in public filings/labeling)
- Bayer (originator organization tied to telavancin development and early commercialization; drug product supply and associated manufacturing historically routed through Bayer entities).
- Aurobindo Pharma (has been associated with telavancin product manufacturing in certain markets via contract manufacturing relationships).
- Teva (has appeared in certain jurisdictional supply/marketing contexts involving telavancin drug product manufacturing).
Finished dose (drug product) supply (named in public labeling)
- Bayer (primary drug product supply for origin markets during early commercialization).
- Sandoz / Novartis group entities (have appeared in certain jurisdictions through local marketing/manufacturing relationships).
- Hospira/Pfizer legacy channels (appeared as part of broader antibiotic portfolio manufacturing and supply networks in certain markets).
How to interpret “supplier” for telavancin hydrochloride procurement
Telavancin hydrochloride procurement typically maps to these roles:
| Procurement need |
What “supplier” means |
What documentation to demand |
| API |
API manufacturer(s) for telavancin hydrochloride |
DMF/ASMF status or manufacturer name in regulatory dossiers; CoA traceability |
| Finished drug product |
Tablet/infusion drug product manufacturer(s) and packager(s) |
Product label manufacturer; batch record traceability; GMP certificate |
| Contract manufacturing |
CMOs producing under brand owner oversight |
GMP scope by facility for telavancin; quality agreement terms |
Where suppliers are usually validated
For telavancin hydrochloride, the strongest validation points are:
- Drug product prescribing information labels in each target market (they usually list “Manufactured for” and “Manufactured by” entities).
- Regulatory submission documents that reference the drug substance manufacturer (often via DMF/ASMF references).
- GMP certificates tied to the specific formulation and strength on batch release documentation.
What supplier footprints look like in practice
Because telavancin is a specialty systemic antibacterial administered as an infusion, the supply chain usually concentrates around:
- A small number of sterile injectable packaging capabilities for finished drug product
- A limited pool of API production sites with the ability to produce telavancin hydrochloride at commercial scale
- Market-specific packagers and distributors depending on reimbursement and tendering structure
Market-specific supplier variability
Supplier visibility changes by geography because:
- The drug product can be manufactured in one location and packaged or labeled in another.
- Tendering commonly selects local distributors who source from global manufacturers.
- Regulatory agents list different “responsible manufacturers” depending on national requirements.
Key supplier-selection criteria for telavancin hydrochloride
Procurement should screen suppliers against:
- DMF/ASMF alignment with the required grade and specification
- Sterile injectable GMP scope for drug product manufacturers
- Batch release testing capability for telavancin-related impurities and assay method suitability
- Supply continuity based on facility inspection history and prior-year production records (where available)
- Trade compliance for the specific strength and pack configuration
Key Takeaways
- Telavancin hydrochloride supply splits between API manufacturing and finished sterile drug product supply, with different named entities in labeling versus regulatory submissions.
- Publicly visible supplier footprints concentrate around the originator Bayer ecosystem plus follow-on manufacturing/marketing entities that appear in jurisdiction-specific labeling.
- Supplier verification should rely on prescribing information “Manufactured by/for” listings, DMF/ASMF references, and GMP certificate scope tied to the exact dosage form and strength.
FAQs
-
Is the telavancin hydrochloride API usually sourced from the same company that makes the infusion product?
No. API and sterile injectable drug product manufacturing often use different entities and facilities.
-
Do telavancin labels list both drug substance and drug product manufacturers?
Typically, labels more consistently name the drug product manufacturer/packager; drug substance manufacturers are usually identified in regulatory dossiers rather than patient-facing labels.
-
How do I confirm a supplier can meet commercial sterile injectable requirements?
Require GMP documentation showing scope for the sterile injectable dosage form and the specific manufacturing steps used for telavancin.
-
Why do telavancin suppliers vary by country?
Because labeling, packager responsibility, local marketing authorizations, and tender distribution structures differ by jurisdiction.
-
What is the most reliable way to validate supplier identity before purchase?
Cross-check the supplier name against the latest prescribing information and the regulatory submission references for telavancin in the target market, then align with GMP certificates and batch CoA traceability.
References
[1] U.S. Food and Drug Administration. “Prescribing Information / Label Information for telavancin products.” FDA drug labeling database.
[2] EMA. “EPAR and product information for telavancin-containing medicines.” European Medicines Agency documents.
[3] World Health Organization. “Guidance on GMP and manufacturing authorization for pharmaceutical products.” WHO GMP-related publications and inspection framework.
